Prevalence and treatment of atherogenic dyslipidemia in the primary prevention of cardiovascular disease in Europe: EURIKA, a cross-sectional observational study

BMC Cardiovascular Disorders

Research Article

Claudio Borghi¹  Karin M. Henriksson²  José R. Banegas³  Guy De Backer⁴  Eliseo Guallar⁵  David Hajage⁶  Carine Roy⁶  Jean Dallongeville⁷  Julian P. Halcox⁸  Joep Perk⁹ 

[1] Department of Internal Medicine, Ageing and Clinical Nephrology, University of Bologna, Bologna, Italy;Department of Medical Sciences, Uppsala University, Uppsala, Sweden;Department of Preventive Medicine and Public Health, School of Medicine, Universidad Autónoma de Madrid/IdiPaz and CIBER of Epidemiology and Public Health (CIBERESP), Madrid, Spain;Department of Public Health, University of Ghent, Ghent, Belgium;Departments of Epidemiology and Medicine and Welch Center of Prevention, Epidemiology and Clinical Research, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA;INSERM CIC-EC 1425 and Département d’Épidémiologie et Recherche Clinique, Assistance Publique–Hôpitaux de Paris, Hôpital Bichat, Paris, France;INSERM U 744, Institut Pasteur de Lille, Université Lille-Nord de France, Lille, France;Institute of Life Sciences 2, Swansea University College of Medicine, Singleton Park, SA2 8PP, Swansea, UK;School of Health and Caring Sciences, Linnaeus University, Kalmar, Sweden;

关键词: Atherogenic dyslipidemia;    Cardiovascular disease;    Epidemiology;    Risk factors/global assessment;   

DOI  :  10.1186/s12872-017-0591-5

 received in 2017-01-18, accepted in 2017-06-05,  发布年份 2017

来源: Springer

【 摘 要 】

BackgroundAtherogenic dyslipidemia is associated with poor cardiovascular outcomes, yet markers of this condition are often ignored in clinical practice. Here, we address a clear evidence gap by assessing the prevalence and treatment of two markers of atherogenic dyslipidemia: elevated triglyceride levels and low levels of high-density lipoprotein cholesterol.MethodsThis cross-sectional observational study assessed the prevalence of two atherogenic dyslipidemia markers, high triglyceride levels and low high-density lipoprotein cholesterol levels, in the study population from the European Study on Cardiovascular Risk Prevention and Management in Usual Daily Practice (EURIKA; N = 7641; of whom 51.6% were female and 95.6% were White/Caucasian). The EURIKA population included European patients, aged at least 50 years with at least one cardiovascular risk factor but no history of cardiovascular disease.ResultsOver 20% of patients from the EURIKA population have either triglyceride or high-density lipoprotein cholesterol levels characteristic of atherogenic dyslipidemia. Furthermore, the proportions of patients with one of these markers were higher in subpopulations with type 2 diabetes mellitus or those already calculated to be at high risk of cardiovascular disease. Approximately 55% of the EURIKA population who have markers of atherogenic dyslipidemia are not receiving lipid-lowering therapy.ConclusionsA considerable proportion of patients with at least one major cardiovascular risk factor in the primary cardiovascular disease prevention setting have markers of atherogenic dyslipidemia. The majority of these patients are not receiving optimal treatment, as specified in international guidelines, and thus their risk of developing cardiovascular disease is possibly underestimated.Trial registrationThe present study is registered with ClinicalTrials.gov (ID: NCT00882336).

【 授权许可】

CC BY   
© The Author(s). 2017